Sheel Biotech (NSE:SHEEL) Piotroski F-Score: 7 (As of Jul. 26, 2026) — 17% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHEEL Sheel Biotech Ltd NSE:SHEEL
18 GF Score
Price ₹68.00
! 2 Warning Signs
View Full Analysis

What is Sheel Biotech Piotroski F-Score?

Sheel Biotech NSE:SHEEL 18 Piotroski F-Score is 7 as of Jul. 26, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates NSE:SHEEL with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,912 Consumer Packaged Goods companies, Sheel Biotech ranks better than 88.34% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sheel Biotech has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Sheel Biotech's Piotroski F-Score or its related term are showing as below:

NSE:SHEEL' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 7

During the past 5 years, the highest Piotroski F-Score of Sheel Biotech was 7. The lowest was 4. And the median was 6.

Sheel Biotech  (NSE:SHEEL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sheel Biotech Piotroski F-Score Related Terms


Sheel Biotech Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sheel Biotech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sheel Biotech Piotroski F-Score Chart

Sheel Biotech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
N/A N/A 6.00 4.00 7.00

Sheel Biotech Semi-Annual Data
Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score N/A N/A 6.00 4.00 7.00

NSE:SHEEL vs ADM, BG, TSN: Piotroski F-Score Comparison

For the Farm Products subindustry, Sheel Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sheel Biotech Piotroski F-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sheel Biotech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sheel Biotech's Piotroski F-Score falls into.


NSE:SHEEL
18GF Score
Sheel Biotech Ltd NSE:SHEEL
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹118 Mil.
Cash Flow from Operations was ₹-176 Mil.
Revenue was ₹1,100 Mil.
Gross Profit was ₹421 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (1132.826 + 1457.843) / 2 = ₹1295.3345 Mil.
Total Assets at the begining of this year (Mar25) was ₹1,133 Mil.
Long-Term Debt & Capital Lease Obligation was ₹12 Mil.
Total Current Assets was ₹1,278 Mil.
Total Current Liabilities was ₹170 Mil.
Net Income was ₹108 Mil.

Revenue was ₹1,018 Mil.
Gross Profit was ₹367 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (1059.466 + 1132.826) / 2 = ₹1096.146 Mil.
Total Assets at the begining of last year (Mar24) was ₹1,059 Mil.
Long-Term Debt & Capital Lease Obligation was ₹48 Mil.
Total Current Assets was ₹1,011 Mil.
Total Current Liabilities was ₹240 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sheel Biotech's current Net Income (TTM) was 118. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sheel Biotech's current Cash Flow from Operations (TTM) was -176. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=117.564/1132.826
=0.1037794

ROA (Last Year)=Net Income/Total Assets (Mar24)
=107.554/1059.466
=0.10151718

Sheel Biotech's return on assets of this year was 0.1037794. Sheel Biotech's return on assets of last year was 0.10151718. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sheel Biotech's current Net Income (TTM) was 118. Sheel Biotech's current Cash Flow from Operations (TTM) was -176. ==> -176 <= 118 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=12.438/1295.3345
=0.00960215

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=48.225/1096.146
=0.04399505

Sheel Biotech's gearing of this year was 0.00960215. Sheel Biotech's gearing of last year was 0.04399505. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1278.274/169.728
=7.53130892

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1010.918/240.162
=4.20931704

Sheel Biotech's current ratio of this year was 7.53130892. Sheel Biotech's current ratio of last year was 4.20931704. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sheel Biotech's number of shares in issue this year was 17.573. Sheel Biotech's number of shares in issue last year was 20.353. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=420.723/1100.224
=0.38239758

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=366.849/1017.525
=0.3605307

Sheel Biotech's gross margin of this year was 0.38239758. Sheel Biotech's gross margin of last year was 0.3605307. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1100.224/1132.826
=0.97122065

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1017.525/1059.466
=0.96041308

Sheel Biotech's asset turnover of this year was 0.97122065. Sheel Biotech's asset turnover of last year was 0.96041308. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+1+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sheel Biotech has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Sheel Biotech (NSE:SHEEL) has a Piotroski F-Score of 7 as of Jul. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sheel Biotech and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Sheel Biotech's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Sheel Biotech ranks #223 out of 1912 companies in the Consumer Packaged Goods industry, placing it in the top 11.7%.
Is Sheel Biotech's Piotroski F-Score too high?
Sheel Biotech's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. Sheel Biotech's value of 7 is 40% above this industry median. Based on the distribution chart, Sheel Biotech ranks #223 out of 1912 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Sheel Biotech has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sheel Biotech's Piotroski F-Score compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Sheel Biotech ranks #223 out of 1912 companies for Piotroski F-Score. This places Sheel Biotech in the top 12% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sheel Biotech's value of 7 is 40% above this benchmark. Historically, Sheel Biotech's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Sheel Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,912 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sheel Biotech's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sheel Biotech and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sheel Biotech's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sheel Biotech stock overvalued right now?
Sheel Biotech (NSE:SHEEL) has a current Piotroski F-Score of 7. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 40% above the Consumer Packaged Goods industry median of 5.00. Sheel Biotech's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sheel Biotech (NSE:SHEEL), the current Piotroski F-Score is 7 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sheel Biotech Business Description

Address Guru Ravidas Marg, 8 Balaji Estates, 2nd Floor, Block-C, Kalkaji, South Delhi, New Delhi, IND, 110019
Sheel Biotech Ltd is engaged in the business of growing, developing, processing, and supplying a wide range of plants for field crops, fruits, vegetables, and ornamental plants through tissue culture and organic farming. It manufactures and maintain greenhouses, offer services to farmers and provide training through Farmer Producer Organizations (FPOs). The company also has a Research and Development lab with a capacity of production of 10 million* planting materials which is duly recognized by the Department of Biotechnology (DBT), Government of India.
18GF Score

Get the complete analysis for NSE:SHEEL

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹68.00
Price